Specification
Measurement method: Indirect ELISA
Measurement wavelength: 450 nm
Measurement sample: Serum
Species reactivity: Human
Storage temperature: Keep HRP-conjugated anti-human IgM/IgG antibody at or below -20 ° C.
Keep other reagents and immobilized plate at 2-8 ° C
Expiration date: This product is valid for 5 months after production.
Immobilized antige: SARS-CoV-2 spike protein (S1+S2 domain, mammalian expression system)
Kit contents
1. SARS-CoV-2 spike protein-immobilized plate
2. HRP-conjugated anti-human IgM antibody
3. HRP-conjugated anti-human IgG antibody
4. Washing buffer（10× PBST）
5. Non-fat milk (for blocking buffer)
6. Diluent buffer (10×)
7. R-1: Chromogenic substrate (TMB)
8. R-2: Stop reagent (1 mol/L hydrochloric acid)
9. Microplate seal
×2
20 μL×1
20 μL×1
100 mL×1
×1
50 mL×1
10 mL×2
10 mL×2
Measurement principle
-
The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.
-
After the reaction, the sample is removed by washing.
-
React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human IgM / IgG antibodies.
-
Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.
.png)
Significance of measurement
This kit is a research ELISA kit to detect human IgM and IgG antibodies that recognize the spike protein of SARS-CoV-2, the causative virus of Covid-19.
Virus detection can be broadly divided into two approaches: one is to detect the virus itself, such as PCR method, and the other is to detect the immune response that develops during infection (IgG, IgM, IgA). In common infections, IgM is an antibody produced early in the infection and disappears with relief of symptoms. IgG begins to be produced later than IgM and continues to be produced for months after healing. This is known to reduce the symptoms of the next infection or to prevent the onset of the next infection
Publications using this product
-
Kazuo Imai et al.
Antibody response patterns in COVID-19 patients with different levels of disease severity-Japan
J Med Virol. 2021 Feb 23. PubMed PMID: 33620098.
References
1.)Keiichi Hiramatsu, Standard Textbook of standard microbiology, 11th edition, Medical study (2012)
2.)Anu Haveri , “Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland,” January to February 2020 , Eurosurveillance. Volume 25, Issue 11, 19, Mar 2020.
3.)Wanbing Liu, “Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2”, J Clin Microbiol. 2020 Mar 30.
4.)Li Guo, “Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)”, Clin Infect Dis. 2020 Mar 21.
5.)Juanjuan Zhao, “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”, Clin Infect Dis. 2020 Mar 21.